TScan Therapeutics, Inc.
TCRX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001783328
No open-market purchases or sales by TScan Therapeutics, Inc. insiders were filed in the last 90 days; 60 institutions reported holding it in 13F filings for Q2 2026, worth $35.1M in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding TScan Therapeutics, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 81 | 1 | 89 | +9 |
| Shares | 41.5M | 4.46M | 41.8M | +4.82M (+13.0%) |
| Value | $242.6M | $26.1M | $208.3M | −$8.14M (−3.8%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (20)
Institutions that held TScan Therapeutics, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| BlackRock, Inc. | 4,632,876 | $23.1M | 0.00% |
| Checkpoint Capital L.P. | 825,341 | $4.11M | 2.04% |
| Jacobs Levy Equity Management, Inc | 103,440 | $515.1K | 0.00% |
| ExodusPoint Capital Management, LP | 55,845 | $278.0K | 0.00% |
| Cubist Systematic Strategies, LLC | 32,137 | $160.0K | 0.00% |
| XTX Topco Ltd | 22,438 | $111.7K | 0.01% |
| Mirae Asset Global ETFs Holdings Ltd. | 21,267 | $105.9K | 0.00% |
| Two Sigma Investments, LP | 15,745 | $78.4K | 0.00% |
| SG Americas Securities, LLC | 15,563 | $78.0K | 0.00% |
| AQR Capital Management LLC | 12,913 | $64.3K | 0.00% |
| Susquehanna International Group, LLP | 10,176 | $50.7K | 0.00% |
| US Bancorp | 4,477 | $22.3K | 0.00% |
| Catalyst Funds Management Pty Ltd | 3,200 | $15.9K | 0.00% |
| Macquarie Group Ltd | 1,047 | $5.21K | 0.00% |
| FMR LLC | 425 | $2.12K | 0.00% |
| GAMMA Investing LLC | 142 | $707 | 0.00% |
| Nisa Investment Advisors, LLC | 121 | $603 | 0.00% |
| Sterling Capital Management LLC | 68 | $339 | 0.00% |
| CWM, LLC | 7 | $0 | 0.00% |
| Capital Advisors, Ltd. LLC | 2 | $0 | 0.00% |
Sold out (11)
Institutions that held TScan Therapeutics, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Paradigm Biocapital Advisors LP | 353,886 | $2.07M |
| Citadel Advisors LLC | 157,963 | $924.1K |
| Alpine Global Management, LLC | 137,490 | $804.3K |
| Bank of Montreal | 120,454 | $749.2K |
| Laurion Capital Management LP | 60,400 | $353.3K |
| American Century Companies Inc | 47,481 | $277.8K |
| Squarepoint Ops LLC | 19,290 | $112.8K |
| Man Group plc | 18,651 | $109.1K |
| Marathon Trading Investment Management LLC | 13,600 | $79.6K |
| Privium Fund Management (UK) Ltd | 12,103 | $69.3K |
| Jump Financial, LLC | 10,792 | $63.1K |
Not filed for Q3 2024 yet (1)
Institutions that held TScan Therapeutics, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 4,462,352 | $26.1M |